Barclays PLC Concert Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2019

Aug 14, 2019
BUY
$9.44 - $13.12 $49,088 - $68,224
5,200 Added 32.91%
21,000 $252,000
Q1 2019

May 15, 2019
BUY
$12.07 - $17.54 $190,706 - $277,132
15,800 New
15,800 $191,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CONCERT PHARMACEUTICALS, INC.

CNCE Quotes by TradingView
  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email